Mikkael Sekeres
University of Miami
H-index: 90
North America-United States
Top articles of Mikkael Sekeres
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML | Leukemia | Guillermo Garcia-Manero Nikolai A Podoltsev Megan Othus John M Pagel Jerald P Radich | 2024/1 |
Results From the Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion-Dependent Non-del (5q) Lower-Risk … | Yazan F Madanat Michael R Savona Mikkael A Sekeres Uwe Platzbecker Valeria Santini | 2024/4/5 | |
Combining lenalidomide with erythropoiesis stimulating agents: a party of one | Namrata S Chandhok Mikkael A Sekeres | 2024/2/15 | |
Molecular patterns identify distinct subclasses of myeloid neoplasia (vol 14, 3136, 2023) | Nature Communications | Tariq Kewan Arda Durmaz Waled Bahaj Carmelo Gurnari Laila Terkawi | 2023/5/30 |
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised … | The Lancet | Uwe Platzbecker Valeria Santini Pierre Fenaux Mikkael A Sekeres Michael R Savona | 2024/1/20 |
Author Correction: Molecular patterns identify distinct subclasses of myeloid neoplasia | nature communications | Tariq Kewan Arda Durmaz Waled Bahaj Carmelo Gurnari Laila Terkawi | 2024 |
S165: CONTINUOUS TRANFUSION INDEPENDENCE WITH IMETELSTAT IN HEAVILY TRANSFUSED NON-DEL (5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS … | HemaSphere | Uwe Platzbecker Valeria Santini Pierre Fenaux Mikkael Sekeres Michael Robert Savona | 2023/8/1 |
Improvement of Patient-Reported Outcomes Among Heavily Pretreated Patients with Lower-Risk Myelodysplastic Syndromes and High Transfusion Burden Treated with Imetelstat on the … | Blood | Mikkael A Sekeres Maria Diez-Campelo Amer M Zeidan Uwe Platzbecker Antoine Regnault | 2023/11/28 |
Correlation between Peripheral Blood and Bone Marrow Somatic Mutations Among Patients with Suspected or Established Myelodysplastic Syndromes from the National MDS Study | Blood | Amy E DeZern Johannes Goll Travis L Jensen Sridhar N Srivatsan Nancy K Gillis | 2023/11/28 |
An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML | Blood | Mohamed L Sorror Ted A Gooley Barry E Storer Aaron T Gerds Mikkael A Sekeres | 2023/1/19 |
Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures | Blood, The Journal of the American Society of Hematology | Benjamin Diamond Bachisio Ziccheddu Kylee Maclachlan Justin Taylor Eileen Boyle | 2023/5/11 |
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial | Leukemia | Mikkael A Sekeres Pau Montesinos Jan Novak Jianxiang Wang Deepa Jeyakumar | 2023/10 |
IMerge: Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) with heavily transfusion dependent (TD) non-del (5q) lower … | Amer Methqal Zeidan Uwe Platzbecker Valeria Santini Pierre Fenaux Mikkael A Sekeres | 2023/6/1 | |
Phase 1b/2 Study of Escalating Doses of the NEDD8 Activating Enzyme Inhibitor Pevonedistat Administered in Combination with Standard Induction Therapy (Cytarabine and … | Blood | Carissa M Feliciano Jennifer S Carew Hetty E Carraway Justin M Watts Sharad Khurana | 2023/11/28 |
PB2014: A PHASE 2/3 TRIAL OF ORAL AZACITIDINE IN PATIENTS WITH LOW-OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES | HemaSphere | Guillermo Garcia-Manero Valeria Santini Pierre Fenaux Takahiro Suzuki Mikkael Sekeres | 2023/8/1 |
Quizartinib May be Effective in an Older Population with FLT3-ITD+ AML. | Cancer Network | Mikkael A Sekeres | 2023/7/21 |
S137: IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN FIRST COMPLETE REMISSION PLUS FLT3 INHIBITION WITH QUIZARTINIB IN ACUTE MYELOID LEUKEMIA WITH FLT3-ITD: RESULTS … | HemaSphere | Richard Schlenk Pau Montesinos Antonio Romero-Aguilar Radovan Vrhovac Elżbieta Patkowska | 2023/8/1 |
MDS-572 Continuous Transfusion Independence With Imetelstat in Heavily Transfused Non-Del (5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/Refractory/Ineligible for … | Clinical Lymphoma Myeloma and Leukemia | Uwe Platzbecker Valeria Santini Pierre Fenaux Mikkael Sekeres Michael Savona | 2023/9/1 |
Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Underwent Allogenic Stem Cell … | Blood | Tariq Kewan Waled Bahaj Mai Aly Arda Durmaz Olisaemeka Ogbue | 2022/11/15 |
Patient-Reported Outcomes (PRO) of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naïve, Transfusion-Dependent (TD), Lower-Risk Myelodysplastic … | Blood | Esther Natalie Oliva Uwe Platzbecker Matteo Giovanni Della Porta Guillermo Garcia-Manero Valeria Santini | 2023/11/28 |
